Glaukos (NYSE:GKOS) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Glaukos (NYSE:GKOS – Get Rating) in a research note published on Thursday. The firm issued a sell rating on the medical instruments supplier’s stock.

Several other equities analysts have also weighed in on the company. Stephens cut their target price on Glaukos from $69.00 to $68.00 and set an overweight rating on the stock in a report on Wednesday, December 28th. JPMorgan Chase & Co. raised their target price on Glaukos from $42.00 to $48.00 and gave the company a neutral rating in a report on Thursday, February 23rd. Mizuho initiated coverage on Glaukos in a report on Thursday, December 22nd. They set a neutral rating and a $48.00 target price on the stock. William Blair restated an outperform rating on shares of Glaukos in a report on Wednesday, February 22nd. Finally, Needham & Company LLC dropped their price objective on Glaukos from $58.00 to $57.00 and set a buy rating on the stock in a research note on Thursday, February 23rd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, Glaukos presently has a consensus rating of Hold and an average price target of $56.67.

Glaukos Price Performance

Shares of NYSE:GKOS opened at $48.02 on Thursday. The company has a current ratio of 6.13, a quick ratio of 5.61 and a debt-to-equity ratio of 0.67. Glaukos has a 1 year low of $33.33 and a 1 year high of $64.49. The business has a fifty day simple moving average of $48.80 and a 200 day simple moving average of $49.59. The firm has a market cap of $2.30 billion, a price-to-earnings ratio of -22.98 and a beta of 1.24.

Glaukos (NYSE:GKOS – Get Rating) last posted its earnings results on Wednesday, February 22nd. The medical instruments supplier reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.03. Glaukos had a negative return on equity of 18.51% and a negative net margin of 35.07%. The company had revenue of $71.23 million for the quarter, compared to analyst estimates of $67.71 million. As a group, sell-side analysts predict that Glaukos will post -2.38 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Glaukos

A number of institutional investors have recently made changes to their positions in the business. Voya Investment Management LLC grew its position in Glaukos by 11.3% during the fourth quarter. Voya Investment Management LLC now owns 46,841 shares of the medical instruments supplier’s stock worth $2,046,000 after buying an additional 4,737 shares in the last quarter. Teachers Retirement System of The State of Kentucky grew its position in Glaukos by 4.9% during the fourth quarter. Teachers Retirement System of The State of Kentucky now owns 35,354 shares of the medical instruments supplier’s stock worth $1,545,000 after buying an additional 1,655 shares in the last quarter. Macquarie Group Ltd. grew its position in Glaukos by 5,365.9% during the fourth quarter. Macquarie Group Ltd. now owns 22,465 shares of the medical instruments supplier’s stock worth $981,000 after buying an additional 22,054 shares in the last quarter. Point72 Middle East FZE acquired a new stake in Glaukos during the fourth quarter worth about $189,000. Finally, CI Private Wealth LLC acquired a new stake in Glaukos during the fourth quarter worth about $721,000. 92.17% of the stock is currently owned by institutional investors.

Glaukos Company Profile

(Get Rating)

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B.